# Ipamorelin Research: Mechanism, Key Studies, and the Combination Rationale > Ipamorelin research digest: the GHS-R1a mechanism, the founding selectivity data, human pharmacokinetics, the failed Phase 2 trial, and the published basis for GHRH+GHRP combination stacks. Single-agent findings and combination pharmacology, each kept in its own column and cited to source. ## Start here The ipamorelin research record is unusually lopsided, and it helps to know that before reading it. The animal pharmacology is deep and clean: ipamorelin releases growth hormone potently and selectively, and it does so by a mechanism that pairs naturally with a different class of GH-releasing drug. The human record is shallow and mostly negative: one small pharmacology study and one failed Phase 2 trial. This page walks through the mechanism (how it works), the founding study that defined its selectivity, what little human data exists, the bone-growth and recent animal findings, and the published reason ipamorelin is paired with GHRH analogs like CJC-1295. A few studies cited here use related peptides (GHRP-6, GHRP-2) to establish a *class-level* principle — those are flagged in the text so combination claims are never overstated as ipamorelin-specific. ## Mechanism — a selective ghrelin-receptor agonist Ipamorelin activates the ghrelin / growth hormone secretagogue receptor (GHS-R1a) on pituitary somatotrophs — the GH-producing cells — triggering a pulse of GH release through the Gq/phospholipase-C/calcium pathway. Its signature is what it does *not* do: it leaves ACTH, cortisol, and prolactin essentially untouched even far above its GH threshold [1]. Because it releases GH by a route distinct from growth-hormone-releasing hormone (GHRH), its action is complementary to GHRH rather than redundant — the molecular basis for combination stacks [7]. Downstream, GH can raise hepatic IGF-1, though short rodent studies often show no IGF-1 change, indicating part of the early effect is a direct GH-pulse phenomenon [4]. Peripheral GHS-R signaling also reaches pancreatic islets and enteric neurons, which is why metabolic and gut-motility effects appear in the literature. ## The founding study — defining selectivity Ipamorelin entered the literature in 1998 as "the first selective growth hormone secretagogue" [1]. In primary rat pituitary cells, anaesthetized rats, and conscious swine, it released GH potently — the swine dose for half-maximal effect was 2.3 nmol/kg, against 3.9 nmol/kg for GHRP-6 — yet it did not raise ACTH or cortisol above the GHRH baseline even at doses more than 200-fold above the GH threshold [1]. That single result is why ipamorelin outlived most of its GHRP contemporaries: it decoupled GH release from the stress-axis activation that limited the others. The characterization was acute, not chronic — it says nothing about what repeated dosing does over months. ## Human data — limited and mostly negative Two human datasets exist, and they bracket the whole human record. The first, a population PK/PD study in healthy male volunteers (n=8 per dose, five IV infusions of 4.21–140.45 nmol/kg), found dose-proportional kinetics, a terminal half-life of about 2 hours, clearance of 0.078 L/h/kg, and a single GH pulse peaking near 40 minutes after dosing [2]. The second, the only published Phase 2 RCT (NCT00672074), gave 0.03 mg/kg IV twice daily for up to 7 days to 114 bowel-resection patients and **missed its primary endpoint**: median time to first tolerated meal was 25.3 hours with ipamorelin versus 32.6 hours with placebo (p=0.15) [3]. Treatment-emergent adverse events occurred in 87.5% of the ipamorelin arm versus 94.8% of placebo — no ipamorelin-specific safety signal in that short window, but no efficacy either [3]. ## Bone growth and the most recent in-vivo finding In adult female Sprague-Dawley rats, subcutaneous ipamorelin at 18, 90, and 450 micrograms/day (divided three times daily for 15 days) dose-dependently raised the longitudinal bone-growth rate from 42 micrometers/day on vehicle to 44, 50, and 52 — with no change in total IGF-1, IGF-binding proteins, or bone-turnover markers [4]. The decoupling of a skeletal effect from systemic IGF-1 points to a local, GH-pulse-driven mechanism. The freshest in-vivo data is a 2024 ferret study: intraperitoneal ipamorelin (1–3 mg/kg) inhibited cisplatin-induced body-weight loss by roughly 24% during the delayed phase, but had no anti-emetic effect — in contrast to central anamorelin, which cut acute emesis by 60% [5]. The weight-protection effect was peripheral. ## The combination rationale — why GHRH + GHRP The pharmacological case for stacking is class-level and well documented. A comprehensive review established that all GHRPs act synergistically with GHRH and are partially resistant to the inhibitory signals — glucose, free fatty acids, somatostatin — that nearly abolish GHRH on its own [7]. A neuroendocrine review adds the circuit detail: ghrelin (and synthetic GHS-R1a agonists by extension) co-localizes with GHRH neurons, facilitates GHRH release by inhibiting somatostatin, and synergizes with GHRH at the pituitary — dual amplification [9]. In lambs, low-dose GHRP-6 plus GHRH produced higher GH peak and area-under-curve than GHRH alone (p<0.05) [10]. The long-acting GHRH partner most discussed with ipamorelin, CJC-1295, produced dose-dependent 2- to 10-fold GH increases for six-plus days and 1.5- to 3-fold sustained IGF-1 elevation after a single subcutaneous dose in healthy adults, while preserving pulsatile secretion [11]. Note carefully: studies [7], [9], and [10] use related peptides or review data to establish a *class* principle, and [11] is on CJC-1295, not ipamorelin. The combination of ipamorelin and CJC-1295 has not itself been tested for any outcome. ## Is ipamorelin FDA approved Is ipamorelin FDA approved? No. Ipamorelin has never been approved by the FDA — or by any other regulatory authority — as a drug for any indication. It was investigated for postoperative ileus (NCT00672074) but never approved, and that trial failed its primary endpoint [3]. In 2024 the FDA removed ipamorelin acetate from Category 2 of the interim Section 503A bulk drug substances list following nominator withdrawal, and reviewed both the acetate and free base at the October 29, 2024 Pharmacy Compounding Advisory Committee meeting; it is not an approved bulk substance for compounding. It is marketed only as a research chemical, and it is prohibited in sport at all times under WADA category S2 [12]. ## Ipamorelin vs tesamorelin Ipamorelin vs tesamorelin is a comparison of two different mechanisms, not two versions of one drug. Ipamorelin is a GHRP — it acts on the ghrelin receptor (GHS-R1a) to release GH [1]. Tesamorelin is a GHRH analog — it acts on the GHRH receptor. The most consequential difference is regulatory: tesamorelin is an approved drug (for a specific HIV-associated condition), whereas ipamorelin has no approved indication anywhere and failed its only Phase 2 trial [3]. Mechanistically the two are *complementary classes*, which is why a GHRP is typically paired with a GHRH analog rather than swapped for one; the class-level synergy between GHRP and GHRH is documented across the review literature [7]. --- A Carbon-plain reading of the ipamorelin record: the selective GH pulse and the ~2-hour human half-life logged where the studies confirm them, the failed Phase 2 trial and the blank long-term-safety line set in equal type, and the CJC-1295 stack read as class pharmacology rather than a tested product — the word 'safe' here naming a question we keep open, with no clinic behind the page and nothing dosed, compounded, prescribed, or sold.